Arena Pharmaceuticals, Inc. (NASDAQ:ARNA)

CAPS Rating: 2 out of 5

A clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs in four major therapeutic areas: cardiovascular, central nervous system, inflammatory and metabolic diseases.

Recs

0
Player Avatar EnigmaDude (96.49) Submitted: 6/19/2012 12:54:23 PM : Underperform Start Price: $10.24 ARNA Score: +12.96

Stock is priced as if FDA has already approved lorcaserin.

Featured Broker Partners


Advertisement